The full article from the French financial newspaper is available here : Acticor Biotech agit contre l’AVC avec un anticorps monoclonal
Science & Santé, the French National Institute of Health and Medical Research (Inserm) magazine, featured Acticor Biotech in its September-October 2014 issue (N°21). Full article in French about “one of the most promising French Biotech of the time”: Acticor Biotech Les AVC en ligne de mire
Biotechinfo.fr, the biotechnology newsletter, interviewed Martine Jandrot-Perrus and Philippe Billiald about the promising development of Acticor’s product for ischemic stroke.
Acticor Biotech, a new biotechnology company entirely dedicated to the development of an innovative therapeutic strategy for a safe and effective emergency treatment of ischemic strokes is opening its capital to crowdfunding. More details about the company.